BlackRock
NDRM

BlackRock’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

BlackRock’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-175,858
Closed -$6.84M – 5136
2017
Q3 		$6.84M Buy
175,858
+2,920
+2% +$107K ﹤0.01% 3367
2017
Q2 		$5.17M Buy
172,938
+23,461
+16% +$608K ﹤0.01% 3462
2017
Q1 		$3.97M Buy
149,477
+149,177
+49,726% +$3.7M ﹤0.01% 3454
2016
Q4 		$7K Buy
+300
New +$5.61K ﹤0.01% 3478

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

BlackRock's NDRM Position: Q4 2017 in Review

BlackRock sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 175,858 shares — an estimated $6.84M sold.

BlackRock first reported a position in NDRM in Q4 2016 and held it in 4 quarters. The position peaked at $6.84M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • BlackRock reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • BlackRock sold 175,858 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $6.84M.
  • BlackRock first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2016 and held it in 4 quarters.
  • BlackRock's NeuroDerm Ltd. Ordinary Shares position peaked at $6.84M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on BlackRock's 13F filing for Q4 2017, filed 9 Feb 2018.